Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy

医学 转甲状腺素 安慰剂 多发性神经病 内科学 淀粉样变性 生活质量(医疗保健) 临床终点 物理疗法 随机对照试验 外科 病理 护理部 替代医学
作者
Teresa Coelho,Wilson Marques,Noel R. Dasgupta,Chi‐Chao Chao,Yeşim Parman,Marcondes C. França,Yuh‐Cherng Guo,Jonas Wixner,Long‐Sun Ro,Cristian Calandra,Pedro André Kowacs,John L. Berk,Laura Obici,Fábio Barroso,Markus Weiler,Isabel Conceição,Shiangtung W. Jung,Gustavo Büchele,Michela Brambatti,Jersey Chen
出处
期刊:JAMA [American Medical Association]
卷期号:330 (15): 1448-1448 被引量:224
标识
DOI:10.1001/jama.2023.18688
摘要

Importance: Transthyretin gene silencing is an emerging treatment strategy for hereditary transthyretin (ATTRv) amyloidosis. Objective: To evaluate eplontersen, an investigational ligand-conjugated antisense oligonucleotide, in ATTRv polyneuropathy. Design, Setting, and Participants: NEURO-TTRansform was an open-label, single-group, phase 3 trial conducted at 40 sites across 15 countries (December 2019-April 2023) in 168 adults with Coutinho stage 1 or 2 ATTRv polyneuropathy, Neuropathy Impairment Score 10-130, and a documented TTR variant. Patients treated with placebo from NEURO-TTR (NCT01737398; March 2013-November 2017), an inotersen trial with similar eligibility criteria and end points, served as a historical placebo ("placebo") group. Interventions: Subcutaneous eplontersen (45 mg every 4 weeks; n = 144); a small reference group received subcutaneous inotersen (300 mg weekly; n = 24); subcutaneous placebo weekly (in NEURO-TTR; n = 60). Main Outcomes and Measures: Primary efficacy end points at week 65/66 were changes from baseline in serum transthyretin concentration, modified Neuropathy Impairment Score +7 (mNIS+7) composite score (scoring range, -22.3 to 346.3; higher scores indicate poorer function), and Norfolk Quality of Life Questionnaire-Diabetic Neuropathy (Norfolk QoL-DN) total score (scoring range, -4 to 136; higher scores indicate poorer quality of life). Analyses of efficacy end points were based on a mixed-effects model with repeated measures adjusted by propensity score weights. Results: Among 144 eplontersen-treated patients (mean age, 53.0 years; 69% male), 136 (94.4%) completed week-66 follow-up; among 60 placebo patients (mean age, 59.5 years; 68% male), 52 (86.7%) completed week-66 follow-up. At week 65, adjusted mean percentage reduction in serum transthyretin was -81.7% with eplontersen and -11.2% with placebo (difference, -70.4% [95% CI, -75.2% to -65.7%]; P < .001). Adjusted mean change from baseline to week 66 was lower (better) with eplontersen vs placebo for mNIS+7 composite score (0.3 vs 25.1; difference, -24.8 [95% CI, -31.0 to -18.6; P < .001) and for Norfolk QoL-DN (-5.5 vs 14.2; difference, -19.7 [95% CI, -25.6 to -13.8]; P < .001). Adverse events by week 66 that led to study drug discontinuation occurred in 6 patients (4%) in the eplontersen group vs 2 (3%) in the placebo group. Through week 66, there were 2 deaths in the eplontersen group consistent with known disease-related sequelae (cardiac arrhythmia; intracerebral hemorrhage); there were no deaths in the placebo group. Conclusions and Relevance: In patients with ATTRv polyneuropathy, the eplontersen treatment group demonstrated changes consistent with significantly lowered serum transthyretin concentration, less neuropathy impairment, and better quality of life compared with a historical placebo. Trial Registration: ClinicalTrials.gov Identifier: NCT04136184; EU Clinical Trials Register: EudraCT 2019-001698-10.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
魏伯安发布了新的文献求助10
刚刚
情怀的应助被喵呜啦啦啦啦采纳,获得30
刚刚
冰苏打完成签到,获得积分10
刚刚
zzh发布了新的文献求助10
1秒前
干净的鸣凤完成签到,获得积分10
1秒前
1秒前
柴六斤发布了新的文献求助10
2秒前
快乐再出发完成签到,获得积分10
2秒前
2秒前
香蕉觅云的应助被zhangyupei采纳,获得10
2秒前
zk812926发布了新的文献求助20
3秒前
bontayu完成签到,获得积分10
3秒前
Zephyr完成签到,获得积分10
4秒前
firedouble完成签到,获得积分10
4秒前
完美静蕾发布了新的文献求助30
4秒前
elodie完成签到,获得积分10
4秒前
4秒前
bkagyin的应助被Vivia采纳,获得10
5秒前
勤恳浩然完成签到,获得积分10
5秒前
5秒前
科目三的应助被祖山药采纳,获得10
6秒前
蔡蔡完成签到,获得积分10
6秒前
7秒前
爆米花的应助被科研通管家采纳,获得10
7秒前
7秒前
7秒前
Tuniverse_发布了新的文献求助10
7秒前
Ava的应助被科研通管家采纳,获得10
7秒前
嘻嘻哈哈的应助被akl采纳,获得10
7秒前
JamesPei的应助被科研通管家采纳,获得10
8秒前
zmm1发布了新的文献求助10
8秒前
wanci的应助被科研通管家采纳,获得10
8秒前
8秒前
脑洞疼的应助被科研通管家采纳,获得10
8秒前
爆米花的应助被科研通管家采纳,获得10
8秒前
FashionBoy的应助被科研通管家采纳,获得10
8秒前
深情安青的应助被科研通管家采纳,获得10
8秒前
香蕉觅云的应助被科研通管家采纳,获得10
8秒前
搜集达人的应助被科研通管家采纳,获得10
8秒前
丰富的草莓完成签到,获得积分10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8182014
求助须知:如何正确求助?哪些是违规求助? 9571728
关于积分的说明 21819478
捐赠科研通 7778441
什么是DOI,文献DOI怎么找? 3433580
关于科研通互助平台的介绍 2557781
邀请新用户注册赠送积分活动 2479640